Medication and food issues for overactive bladder/lower urinary tract symptoms: When do we eat?

Current Bladder Dysfunction Reports

Volumn 4, Issue 2, 2009, Pages 93-97

  Maltz, Helene C ^b   Staskin, David R ^b   Zoltan, Edward ^a  

^a NEW YORK METHODIST HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873288121     PISSN: 19317212     EISSN: 19317220     Source Type: Journal    
DOI: 10.1007/s11884-009-0014-2     Document Type: Article

References (32)

1. Toothaker RD, Welling PG: The effect of food on drug bioavailability. Ann Rev Pharmacol Toxicol 1980, 20: 173-199.
2. Welling PG: Interactions affecting drug absorption. Clin Pharmacokinet 1984, 9: 404-434.
3. Yamreudeewong W, Henann NE, Fazio A, et al.: Drug-food interactions in clinical practice. J Fam Pract 1995, 40: 376-384.
4. Sathyan G, Hu W, Gupta SK: Lack of effect of food on the pharmacokinetics of an extended-release oxybutynin formulation. J Clin Pharmacol 2001, 41: 187-192.
5. Boyle P, Robertson C, Mazzetta C, et al.: The prevalence of lower urinary tract symptoms in men and women in four centres: the UrEpik study. BJU Int 2003, 92: 409-414.
6. Skerjanec A: The clinical pharmacokinetics of darifenacin. Clin Pharmacokinet 2006, 45: 325-350.
7. Thomas TM, Plymat KR, Blannin J, Meade TW: Prevalence of urinary incontinence. BMJ 1980, 281: 1243-1245.
8. Jackson S: The patient with an overactive bladder-symptoms and quality of life issues. Urology 1997, 50(Suppl 6A): 18-22.
9. Lee M: Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia. Am J Health Syst Pharm 2003, 60: 1426-1439.
10. Girman CJ, Jacobsen SJ, Tsukamoto T, et al.: Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998, 51: 428-436.
11. Guay DRP: Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003, 42: 1243-1285.
12. Lukkari E, Aranko K, Juhakoski A, et al.: Effect of time interval between food and drug ingestion on the absorption of oxybutynin from a controlled-release tablet. Pharmacol Toxicol 1997, 81: 31-34.
13. Lukkari E, Castrèn-Kortekangas P, Juhakoski A, et al.: Effect of food on the bioavailability of oxybutynin from a controlled release tablet. Eur J Clin Pharmacol 1996, 50: 221-223.
14. Olsson B, Brynne N, Johansson C, Amberg H: Food increases the bioavailability of tolterodine but not effective exposure. J Clin Pharmacol 2001, 41: 298-304.
15. Wein AJ, Rovner ES: The overactive bladder: an overview for primary health care providers. Int J Fertil 1999, 44: 56-66.
16. Olsson B, Szamosi J: Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder. Clin Pharmacokinet 2001, 40: 135-143.
17. Doroshyenko O, Jetter A, Odenthal KP, Fuhr U: Clinical pharmacokinetics of trospium chloride. Clin Pharmacokinet 2005, 44: 701-720.
18. Sanctura [package insert]. New Brunswick, NJ: Esprit Pharmaceuticals; 2006.
19. Sanctura XR [package insert]. New Brunswick, NJ: Esprit Pharmaceuticals; 2008.
20. Uchida T, Krauwinkel WJ, Mulder H, Smulders RA: Food does not affect the pharmacokinetics of solifenacin, a new muscarinic receptor antagonist: results of a randomized crossover trial. Br J Clin Pharmacol 2004, 58: 4-7.
21. Proscar [package insert]. Whitehouse Station, NJ: Merck & Co.; 2007.
22. Steiner JF: Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 1996, 30: 16-27.
23. Avodart [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2008.
24. Chung M, Vashi V, Puente J, et al.: Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic (GITS) formulation. Br J Clin Pharmacol 1999, 48: 678-687.
25. McNeil JJ, Drummer OH, Raymond K, et al.: The influence of food on the oral bioavailability of terazosin. Br J Clin Pharmacol 1991, 32: 775-776.
26. Uroxatral [package insert]. Bridgewater, NJ: Sanofi-Aventis; 2007.
27. Flomax [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2008.
28. Paine MF, Criss AB, Watkins PB: Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab Dispos 2004, 32: 1146-1153.
29. Kiani J, Imam SZ: Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr J 2007, 6: 33.
30. Bailey DG, Malcolm J, Arnold O, Spence JD: Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998, 46: 101-110.
31. Sadowski DC: Drug interactions with antacids: mechanism and clinical significance. Drug Saf 1994, 11: 395-407.
32. Sulli MM, Ezzo DC: Drug interactions with vitamins and minerals. US Pharm 2007, 1: 42-55.